Provided by Tiger Fintech (Singapore) Pte. Ltd.

Valneva SE

6.16
-0.1200-1.91%
Post-market: 6.160.00000.00%19:46 EDT
Volume:11.28K
Turnover:68.97K
Market Cap:523.80M
PE:-5.29
High:6.18
Open:6.15
Low:6.02
Close:6.28
Loading ...

Press Release: Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Dow Jones
·
20 Mar

High Growth Tech Stocks In Europe For March 2025

Simply Wall St.
·
10 Mar

VALNEVA Declaration of shares and voting rights: February 28, 2025

GlobeNewswire
·
06 Mar

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

GlobeNewswire
·
03 Mar

Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq

TIPRANKS
·
01 Mar

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

GlobeNewswire
·
01 Mar

Valneva Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Mar

Analysts Offer Insights on Healthcare Companies: Valneva (VALN) and Butterfly Network (BFLY)

TIPRANKS
·
28 Feb

Valneva Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
19 Feb

Valneva price target lowered to $17 from $18 at H.C. Wainwright

TIPRANKS
·
19 Feb

Valneva Expects Further Sales Growth

Dow Jones
·
18 Feb

Valneva 2025 Financial Outlook: Sales Revenue Projected At €170M-€180M, Total Revenue To Reach €180M-€190M; R&D Investments Of €90M-€100M

Benzinga
·
18 Feb

Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M

Benzinga
·
18 Feb

Press Release: Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Dow Jones
·
18 Feb

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

GlobeNewswire
·
18 Feb

Shareholding declaration Valneva SE - January 2025

GlobeNewswire
·
07 Feb

Valneva jumps 19% after chikungunya vaccine wins UK approval

TIPRANKS
·
06 Feb

MHRA grants Valneva marketing authorization for chikungunya vaccine

TIPRANKS
·
06 Feb

Valneva Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Feb

Valneva Gets Marketing Authorization in UK for Chikungunya Vaccine; Shares Rise

MT Newswires Live
·
05 Feb